Our Model
Since 2010, Oxeltis has supported numerous drug discovery projects through its expertise in medicinal chemistry and high-value complex organic synthesis.
To deliver even greater value, we’ve forged a strategic preclinical consortium with Molecular Forecaster and Partex.ai, creating a powerhouse for early-stage drug discovery. Together, we combine cutting-edge expertise to drive innovation—faster, smarter, and with unmatched precision.
The Consortium
A Strategic Preclinical Consortium
This alliance brings together three complementary areas of expertise:
Oxeltis
Medicinal chemistry and complex organic synthesis
Molecular Forecaste
Computer-Aided Drug Design
(CADD)
Partex.ai
Biological testing and
validation
Together, we provide a seamless path from computational design to biological validation.
Molecular Forecaster: Advanced Computational Drug Design
Partner Spotlight 1
Molecular Forecaster, our Computer-Aided Drug Design (CADD) partner, brings predictive modeling and computational expertise to the table.Their advanced tools enable the design and optimization of drug candidates with precision, significantly reducing the time and cost of identifying promising compounds.By leveraging their expertise, we ensure that every molecule designed is scientifically sound and tailored to your project’s needs.
Partex.ai: Biological Testing & Validation
Partner Spotlight 2
Partex.ai, our biological testing partner, specializes in enzymatic and cellular assays.Their high-throughput screening and validation capabilities provide critical biological insights, confirming the efficacy, selectivity, and safety of your compounds.This step is essential to bridge the gap between computational predictions and real-world biological activity.
An End-to-End Drug Discovery Solution
This alliance enables us to provide a seamless, end-to-end solution—from computational design to biological validation—without the rigidity of traditional large CROs.
Agility, Flexibility and Scientific Partnership
Our model is built on agility and flexibility. Unlike big CROs, we adapt to your needs, not the other way around.No hidden fees, no bureaucratic delays—just science-driven collaboration.Whether you’re exploring new chemical entities, optimizing leads, or validating targets, our consortium combines cutting-edge expertise with the responsiveness of a true partner.
Driving the DMTA Cycle Faster
What sets us apart? We don’t just execute tasks; we integrate with your team to drive the DMTA cycle—Design, Model, Test, Analyze—faster and more efficiently.
- Design:
Oxeltis' synthetic expertise
- Model:
Molecular Forecaster’s predictive modeling
- Test:
Partex.ai’s biological assays and validation
- Analyze:
Integrated insights to accelerate decision-making
This synergy ensures faster iterations, smarter decisions, and higher success rates—all while keeping costs transparent and scalable.
Speed and Precision for Modern Drug Discovery
In a landscape where innovation demands both speed and precision, our consortium delivers both.We’re here to challenge the status quo and help you turn ideas into breakthroughs.
Ready to Accelerate Your Drug Discovery Journey?
Contact us today to explore how our consortium can support your next project.